Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dunn

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
The Lancet. HIV|June 13, 2018
Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance dataManon Ragonnet-Cronin, Stéphane Hué, Emma B Hodcroft, et al.
BMJ Open|December 13, 2019
Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxisAda Miltz, Fiona Lampe, Sheena McCormack, et al.
Antiviral Therapy|March 31, 2011
Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosisAlejandro Arenas-Pinto, Alison Grant, Krishnan Bhaskaran, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South AfricaElizabeth Phillips, John A Bartlett, Ian Sanne, et al.
AIDS (London, England)|March 23, 2017
Hepatitis B serological markers and plasma DNA concentrationsHuw Price, David Dunn, Tamale Zachary, et al.
Pediatric Neurology|December 24, 2014
Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND ChecklistPetrus J de Vries, Vicky H Whittemore, Loren Leclezio, et al.
Plos One|February 6, 2016
Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis PathogenesisMonika Tschochner, Shay Leary, Don Cooper, et al.
Plos One|October 3, 2013
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureSara Lodi, Andrew Phillips, Sarah Fidler, et al.
The Lancet. HIV|May 9, 2017
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort studyJemma O'Connor, Colette Smith, Fiona C Lampe, et al.
HIV Medicine|September 30, 2023
Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) studyAlessandro Cozzi-Lepri, David Dunn, Anna Tostevin, et al.
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
The Lancet. HIV|June 13, 2018
Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance dataManon Ragonnet-Cronin, Stéphane Hué, Emma B Hodcroft, et al.
BMJ Open|December 13, 2019
Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxisAda Miltz, Fiona Lampe, Sheena McCormack, et al.
Antiviral Therapy|March 31, 2011
Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosisAlejandro Arenas-Pinto, Alison Grant, Krishnan Bhaskaran, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South AfricaElizabeth Phillips, John A Bartlett, Ian Sanne, et al.
AIDS (London, England)|March 23, 2017
Hepatitis B serological markers and plasma DNA concentrationsHuw Price, David Dunn, Tamale Zachary, et al.
Pediatric Neurology|December 24, 2014
Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND ChecklistPetrus J de Vries, Vicky H Whittemore, Loren Leclezio, et al.
Plos One|February 6, 2016
Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis PathogenesisMonika Tschochner, Shay Leary, Don Cooper, et al.
Plos One|October 3, 2013
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureSara Lodi, Andrew Phillips, Sarah Fidler, et al.
The Lancet. HIV|May 9, 2017
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort studyJemma O'Connor, Colette Smith, Fiona C Lampe, et al.
HIV Medicine|September 30, 2023
Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) studyAlessandro Cozzi-Lepri, David Dunn, Anna Tostevin, et al.
Pageof 15